Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

189P - Invasive lobular carcinoma in young breast cancer patients: Incidence and clinicopathological characteristics

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Breast Cancer

Presenters

Abeid Athman Omar

Citation

Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687

Authors

A.M. Athman Omar, H.F..A. Masoud, A.M..A. Darwesh

Author affiliations

  • Clinical Oncology And Nuclear Medicine Department, Faculty of Medicine, Alexandria University, 20 - Alexandria/EG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 189P

Background

Invasive lobular carcinoma (ILC) is increasingly recognized as a unique breast cancer histological subtype. We aimed to determine the incidence and clinicopathological characteristics of young breast cancer patients.

Methods

We retrospectively reviewed the records of female patients aged ≤40 diagnosed with lLC, both classic ILC and mixed invasive lobular-ductal carcinoma (ILC-IDC), between 2008 and 2017 in two centres in Alexandria, Egypt. We determined their incidence and clinicopathological characteristics.

Results

Out of the 1228 patients, 4.4% (n=54) were diagnosed with invasive lobular carcinoma, in which 29 out 54 were classic ILC (54%). The median age at diagnosis was 37 years (Range: 24 – 40 years), and 25% had a positive family history of BC. The majority of the patients underwent MRM (82.4%), and nearly a quarter (13.7%) had a multifocal disease. The mean tumour size was 4.4 cm ±2.1, while positive axillary lymph nodes were 6.7±7.7, with TNM stage III being the most common – 64%. All patients had grade 2 tumours. The lymphovascular invasion was present in 65% of the patients. Nearly half (48.6%) had an extracapsular extension. Almost all patients had estrogen/progesterone receptor-positive tumours (97.8%). At a median follow up of 28 months (Range: 2 – 135), 41% of the patients (n=22) developed recurrences. 77% out of the 22 relapses were distant recurrences. The median disease-free survival was 36 months (95% CI: 30.1 – 41.9).

Conclusions

Invasive lobular carcinoma is infrequent in young breast cancer patients. Our results confirm that ILC tumours are frequently intermediate grade and almost exclusively hormone-receptor-positive, even in young breast cancer patients. Distant relapses are the most common, despite the short follow-up.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.